American thyroid association statement on preoperative imaging for thyroid cancer surgery

Thyroid

Volumn 25, Issue 1, 2015, Pages 3-14

  Yeh, Michael W ^a   Bauer, Andrew J ^b   Bernet, Victor A ^c   Ferris, Robert L ^d   Loevner, Laurie A ^e   Mandel, Susan J ^e   Orloff, Lisa A ^f   Randolph, Gregory W ^g   Steward, David L ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; RADIOACTIVE IODINE;

ARTICLE; BENIGN TUMOR; CALCIFICATION; CANCER LOCALIZATION; CANCER SIZE; CANCER SURGERY; CERVICAL LYMPH NODE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOLOGY; DIAGNOSTIC IMAGING; ECHOGENICITY; ECHOGRAPHY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; HUMAN; LYMPH FLOW; LYMPH NODE METASTASIS; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; THYROID CANCER; TREATMENT PLANNING; TUMOR INVASION; ULTRASOUND SCANNER; PATHOLOGY; PRACTICE GUIDELINE; PREOPERATIVE CARE; THYROID GLAND; THYROID NEOPLASMS;

HUMANS; PREOPERATIVE CARE; THYROID GLAND; THYROID NEOPLASMS;

EID: 84920830277     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2014.0096     Document Type: Article

References (60)

1. Mazzaferri EL, Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
2. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB 2003 Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134:946-954; discussion 954-945.
3. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM, American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
4. Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, Randolph GW, Stack BC, Steward DL, Terris DJ, Thompson GB, Tufano RP, Tuttle RM, Udelsman R, American Thyroid Association Surgery Working Group 2009 Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 19:1153-1158.
5. Stack BC, Jr., Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, Sosa JA, Tufano RP 2012 American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid 22:501-508.
6. Koo BS, Choi EC, Park YH, Kim EH, Lim YC 2010 Occult contralateral central lymph node metastases in papillary thyroid carcinoma with unilateral lymph node metastasis in the lateral neck. J Am Coll Surg 210:895-900.
7. Zhao Q, Ming J, Liu C, Shi L, Xu X, Nie X, Huang T 2013 Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol 20:746-752.
8. Ito Y, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A 2007 Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg 31:2085-2091.
9. Langer JE, Mandel SJ 2008 Sonographic imaging of cervical lymph nodes in patients with thyroid cancer. Neuroimaging Clin N Am 18:479-489, vii-viii.
10. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E, Schlumberger M 2007 Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 92:3590-3594.
11. Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim EK 2009 Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 193:871-878.
12. Hwang HS, Orloff LA 2011 Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. Laryngoscope 121:487-491.
13. Kim E, Park JS, Son KR, Kim JH, Jeon SJ, Na DG 2008 Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid 18:411-418.
14. Solbiati L, Osti V, Cova L, Tonolini M 2001 Ultrasound of thyroid, parathyroid glands and neck lymph nodes. Eur Radiol 11:2411-2424.
15. Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M, Arora A, Tolley NS, Palazzo F, Learoyd DL, Sidhu S, Delbridge L, Sywak M, Yeh MW 2011A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery 150:1048-1057.
16. Gimm O, Rath FW, Dralle H 1998 Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg 85: 252-254.
17. Sadowski BM, Snyder SK, Lairmore TC 2009 Routine bilateral central lymph node clearance for papillary thyroid cancer. Surgery 146:696-703; discussion 703-705.
18. Machens A, Hinze R, Thomusch O, Dralle H 2002 Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26:22-28.
19. Khafif A, Medina JE, Robbins KT, Silver CE, Weber RS, Rinaldo A, Owen RP, Shaha AR, Ferlito A 2013 Level V in therapeutic neck dissections for papillary thyroid carcinoma. Head Neck 35:605-607.
20. Lee YS, Shin SC, Lim YS, Lee JC, Wang SG, Son SM, Kim IJ, Lee BJ 2014 Tumor location-dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck 36:887-891.
21. Kuna SK, Bracic I, Tesic V, Kuna K, Herceg GH, Dodig D 2006 Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. J Ultrasound Med 25:1531-1537; quiz 1538-1540.
22. Sipos JA 2009 Advances in ultrasound for the diagnosis and management of thyroid cancer. Thyroid 19:1363-1372.
23. Wunderbaldinger P, Harisinghani MG, Hahn PF, Daniels GH, Turetschek K, Simeone J, O'Neill MJ, Mueller PR 2002 Cystic lymph node metastases in papillary thyroid carcinoma. AJR Am J Roentgenol 178:693-697.
24. Ahuja AT, Ying M, Ho SS, Metreweli C 2001 Distribution of intranodal vessels in differentiating benign from metastatic neck nodes. Clin Radiol 56:197-201.
25. Görges R, Eising EG, Fotescu D, Renzing-Köhler K, Frilling A, Schmid KW, Bockisch A, Dirsch O 2003 Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound 16:191-206.
26. Kim MJ, Kim EK, Park SI, Kim BM, Kwak JY, Kim SJ, Youk JH, Park SH 2008 US-guided fine-needle aspiration of thyroid nodules: indications, techniques, results. Radiographics 28:1869-1886; discussion 1887.
27. Bhatki AM, Brewer B, Robinson-Smith T, Nikiforov Y, Steward DL 2008 Adequacy of surgeon-performed ultrasoundguided thyroid fine-needle aspiration biopsy. Otolaryngol Head Neck Surg 139:27-31.
28. Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S 2006 The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 91:1364-1369.
29. Snozek CL, Chambers EP, Reading CC, Sebo TJ, Sistrunk JW, Singh RJ, Grebe SK 2007 Serum thyroglobulin, highresolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab 92:4278-4281.
30. Cunha N, Rodrigues F, Curado F, Ilheu O, Cruz C, Naidenov P, Rascao MJ, Ganho J, Gomes I, Pereira H, Real O, Figueiredo P, Campos B, Valido F 2007 Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. Eur J Endocrinol 157:101-107.
31. Boi F, Maurelli I, Pinna G, Atzeni F, Piga M, Lai ML, Mariotti S 2007 Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:2115-2118.
32. Grant CS, Stulak JM, Thompson GB, Richards ML, Reading CC, Hay ID 2010 Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006. World J Surg 34:1239-1246.
33. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN 2009 Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092-2098.
34. Cibas ES, Ali SZ 2009 The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 19:1159-1165.
35. Yang J, Schnadig V, Logrono R, Wasserman PG 2007 Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 111:306-315.
36. Banks ND, Kowalski J, Tsai HL, Somervell H, Tufano R, Dackiw AP, Marohn MR, Clark DP, Umbricht CB, Zeiger MA 2008A diagnostic predictor model for indeterminate or suspicious thyroid FNA samples. Thyroid 18:933-941.
37. Yoon JH, Kwak JY, Kim EK, Moon HJ, Kim MJ, Kim JY, Koo HR, Kim MH 2010 How to approach thyroid nodules with indeterminate cytology. Ann Surg Oncol 17:2147-2155.
38. Roy R, Kouniavsky G, Venkat R, Felger EA, Shiue Z, Schneider E, Zeiger MA 2012 The role of preoperative neck ultrasounds to assess lymph nodes in patients with suspicious or indeterminate thyroid nodules. J Surg Oncol 105:601-605.
39. Moon HJ, Kim EK, Yoon JH, Kwak JY 2012 Differences in the diagnostic performances of staging US for thyroid malignancy according to experience. Ultrasound Med Biol 38:568-573.
40. Andersen PE, Kinsella J, Loree TR, Shaha AR, Shah JP 1995 Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 170:467-470.
41. McCaffrey TV, Bergstralh EJ, Hay ID 1994 Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck 16:165-172.
42. From AM, Al Badarin FJ, McDonald FS, Bartholmai BJ, Cha SS, Rihal CS 2010 Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials. Circ Cardiovasc Interv 3:351-358.
43. Yang L, Krefting I, Gorovets A, Marzella L, Kaiser J, Boucher R, Rieves D 2012 Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology 265:248-253.
44. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP, Tuttle RM, The American Thyroid Association Surgical Affairs Committee's Taskforce on Thyroid Cancer Nodal Surgery 2012 The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22:1144-1152.
45. Lesnik D, Cunnane ME, Zurakowski D, Acar GO, Ecevit C, Mace A, Kamani D, Randolph GW 2013 Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. Head Neck 36:191-202.
46. Ahn JE, Lee JH, Yi JS, Shong YK, Hong SJ, Lee DH, Choi CG, Kim SJ 2008 Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg 32:1552-1558.
47. Padovani RP, Kasamatsu TS, Nakabashi CC, Camacho CP, Andreoni DM, Malouf EZ, Marone MM, Maciel RM, Biscolla RP 2012 One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy. Thyroid 22:926-930.
48. Avram AM 2012 Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med 53:754-764.
49. Francis CL, Nalley C, Fan C, Bodenner D, Stack BC, Jr. 2012 18F-fluorodeoxyglucose and 131I radioguided surgical management of thyroid cancer. Otolaryngol Head Neck Surg 146:26-32.
50. Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ 1999 Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547-1552.
51. Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M 2001 Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42:71-76.
52. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ 1999 [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-2302.
53. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505.
54. Razfar A, Branstetter BF, Christopoulos A, Lebeau SO, Hodak SP, Heron DE, Escott EJ, Ferris RL 2010 Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg 136:120-125.
55. Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL 2008 Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131Inegative thyroid cancer. Ann Surg Oncol 15:286-292.
56. Kim SJ, Lee TH, Kim IJ, Kim YK 2009 Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur J Radiol 70:17-24.
57. Mirallié E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, Bodet-Milin C, Curtet C, Carnaille B, Murat A, Charbonnel B, Kraeber-Bodéré F 2007 Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 142:952-958; discussion 952-958.
58. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Bencherif BB, Joyce JM, Carty SE, Kuffner HA, Avril N 2007 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48:221-226.
59. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M 2009 Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 94:1310-1316.
60. Tuttle RM, Leboeuf R, Martorella AJ 2007 Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 36:753-778, vii.